TY - JOUR
TI - The expression of galectin-3 in breast cancer and its association with chemoresistance: a systematic review of the literature
AU - Boutas, I.
AU - Potiris, A.
AU - Brenner, W.
AU - Lebrecht, A.
AU - Hasenburg, A.
AU - Kalantaridou, S.
AU - Schmidt, M.
JO - Archives of Gynecology and Obstetrics
PY - 2019
VL - 300
TODO - 5
SP - 1113-1120
PB - Springer-Verlag
SN - 0932-0067, 1432-0711
TODO - 10.1007/s00404-019-05292-9
TODO - arsenic trioxide;  carboplatin;  cisplatin;  doxorubicin;  etoposide;  fenretinide;  galectin 3;  mitomycin;  tumor necrosis factor related apoptosis inducing ligand;  antineoplastic agent;  galectin 3;  galectin-3, human, antiapoptotic activity;  breast cancer;  cancer cell;  cancer chemotherapy;  cancer resistance;  cell protection;  cell survival;  DNA damage;  DNA repair;  human;  protein expression;  protein function;  Review;  systematic review;  apoptosis;  breast tumor;  drug effect;  drug resistance;  female;  genetics, Antineoplastic Agents;  Apoptosis;  Breast Neoplasms;  Drug Resistance, Neoplasm;  Female;  Galectin 3;  Humans
TODO - Purpose: Galectin-3 is a Mr 31,000 protein that belongs to a family of carbohydrate-binding proteins. Galectin-3 has already been associated with protection against apoptosis through cell to cell or cell to matrix adhesion processes. It seems that galectin-3 plays an important role in tumor progression, cell growth, invasion and metastasis. Galectin-3 is the only member of the chimeric galectins that has an N-terminal glycine and proline domain and a C-terminal carbohydrate recognition domain that allows galectin-3 to accommodate larger structures such us polylactosaminoglycans and intervene to DNA damage repair process. In this systematic review, our primary goal is to identify the effect of galectin-3 expression in association with drug resistance and apoptosis inhibition in breast cancer. Materials and methods: Scopus and PubMed databases were searched on 26 November 2018 using the following combination of keywords: (galectin-3 OR gal-3 OR LGALS3) AND (breast cancer) AND (chemoresistance OR (drug resistance) OR chemosensitivity). All the articles in English, regardless the time of publication, text availability and species included were initially accepted. Results: In the majority of the included studies, the expression of galectin-3 had a protective role in cell survival via different pathways such as the response to DNA damage and repair or the inhibition of apoptosis after treatment with a chemotherapeutic agent. Conclusion: Galectin-3 expression in breast tumors might be an important factor in the selection of the most suitable treatment. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
ER -